Effectiveness of bariatric metabolic surgery versus glucagon-like peptide-1 receptor agonists for prevention of congestive heart failure
Main finding · Primary incidence of CHFResult — go to the resultAdjusted hazard ratio 0.43 95% CI 0.27–0.68Authors' conclusion
In this study, BMS was associated with a stronger reduction in primary incidence of CHF compared with treatment with GLP-1RA.
Study context
- Population
- Adults with obesity and DM, no prior ischemic heart disease, ischemic stroke or congestive heart failure (CHF); Clalit Health Services members, 2008–20212,205 matched pairs
- Exposure
- Bariatric metabolic surgery vs GLP-1RA
- Outcome
- Primary incidence of congestive heart failure (CHF)
- Follow-up
- Median 6.6 years (up to 12 years)
Methodological detailsobservational, matched 1:1
- Observational
- Matched 1:1
Main finding
Primary incidence of CHF
Adjusted hazard ratio
0.43
95% CI 0.27–0.68
Events by group
BMS vs GLP-1RA
adjusted HR 0.43 (95% CI 0.27–0.68)
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | HR adjusted for weight reduction (95% CI) | |
|---|---|---|
| Primary incidence of CHF, further adjusted for weight reduction | 0.48 (0.28–0.82) | |
| 0.20.5125HR adjusted for weight reduction (log scale) |
Original publication
Effectiveness of bariatric metabolic surgery versus glucagon-like peptide-1 receptor agonists for prevention of congestive heart failure. Nat Med. Published 15 May 2024. doi:10.
Summarised from the published abstract; every number is checked against it